JMJyotsana R. Madan

Jyotsana R. Madan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jyotsana R. Madan has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras

    by Jyotsana Madan, Vijay Kamal Ahuja, Kamal Dua, Susanta Samajdar, Murali Ramchandra, Sanjeev Giri

    In the recent past, proteolysis-targeting chimera (PROTAC) technology has received enormous attention for its ability to overcome the limitations of protein inhibitors and its capability to target undruggable proteins. The PROTAC molecule consists of three components, a ubiquitin E3 ligase ligand, a linker, and a target protein ligand. The application of this technology is rapidly gaining momentum, especially in cancer therapy. In this review, we first look at the history of degraders, followed by a section on the ubiquitin proteasome system (UPS) and E3 ligases used in PROTAC development. PROTACs are dependent on the UPS for degradation of target proteins. We further discuss the scope and design of degraders and mitigation strategies for overcoming the hook effect seen with degraders. As PROTACs do not follow Lipinski’s ‘Rule of 5’, these molecules face drug metabolism and pharmacokinetic challenges. A detailed section on absorption, distribution, metabolism, and excretion of degraders is provided wherein we discuss methodologies and strategies to surmount the challenges faced by these molecules. For understanding PROTAC-mediated degradation, the characterization and measurement of protein levels in cells is important. Currently used techniques and recent advancements in assessment tools for degraders are discussed. Furthermore, we examine the challenges and emerging technologies that need to be focused on in order to competently develop potent degraders. Many companies are working in this area of emerging new modality and a few PROTACs have already entered clinical trials; the details of the trials are included in this review.


  • Efavirenz Loaded Mixed Polymeric Micelles: Formulation, Optimization, and In Vitro Characterization

    by Jyotsana R. Madan, Shrikant G. Dere, Rajendra Awasthi, Kamal Dua

    Efavirenz (EFZ) is a biopharmaceutics classification system (BCS) Class-II, first-line antiretroviral (ARV) drug. However, its utility through the oral route is restricted by its poor solubility. The objective of this study was to formulate EFZ-loaded binary-mixed micelles as a potential carrier for oral administration of EFZ. Rubingh's regular solution theory was used to determine the interaction behavior of the two components (Cremophor RH 40 and Phospholipon 80H) and of the mixed micelles and synergistic behavior was confirmed. The mixed miceller system was formulated using solvent evaporation method and a 32 factorial design was used for the optimization of selected independent variables. Miceller systems were further characterized in terms of morphology, particle size, zeta potential, percent entrapment efficiency, and drug loading. Fourier transform infrared and differential scanning calorimetry measurements confirmed the entrapment of EFZ in the micelles. The optimized formulation presented desirable qualities viz., nanometric size (17.27 ± 0.079), high entrapment efficiency, and good colloidal stability. The prepared optimized micelles can be potential carriers for EFZ in ARV therapies.


  • Open Access

    Middle East Respiratory Syndrome (MERS) Virus—Pathophysiological Axis and the Current Treatment Strategies

    by Abdullah M Alnuqaydan, Abdulmajeed G Almutary, Arulmalar Sukamaran, Brian Tay Wei Yang, Xiao Ting Lee, Wei Xuan Lim, Yee Min Ng, Rania Ibrahim, Thiviya Darmarajan, Satheeshkumar Nanjappan, et al.

    Middle East respiratory syndrome (MERS) is a lethal respiratory disease with its first case reported back in 2012 (Jeddah, Saudi Arabia). It is a novel, si


  • Cocrystals of Apixaban with Improved Solubility and Permeability: Formulation, Physicochemical Characterization, Pharmacokinetic Evaluation, and Computational Studies

    by Jyotsana R. Madan, Savita V. Waghmare, Rajesh B. Patil, Rajendra Awasthi, Kamal Dua

    The objective of the current study was to develop new cocrystals of Apixaban (APX) to improve its solubility and permeability. The molecular interaction between APX and caffeine (CFFN) was further studied by Raman spectroscopy. The results of all eight studied conformers revealed that the synthesized APX-CFFN cocrystals had the highest solubility and permeability. The water solubility and permeability of APX in the cocrystal were simultaneously enhanced as compared with pure APX in the physiological pH environment (pH 6.8 and pH 7.4). The X-ray diffraction analysis revealed that the cocrystal has a component molar ratio of 1:1. This was dominated by a three-dimensional hydrogen bonding supramolecular structure. The in vivo pharmacokinetic (PK) study indicated that the mean area under curve (AUC) of APX from the synthesized cocrystal was enhanced more than three-folds than the pure APX. Tablets of APX and APX-CFFN cocrystals were prepared using direct compression method and evaluated for in vitro dissolution profile in phosphate buffers (pH 6.8 and pH 7.4). Computational investigations with molecular dynamics simulations also supported the formation of stable cocrystals. The drug release of APX from the tablets was considerably increased when compared with the pure APX in both pH conditions and it was found to increase with an increase in media pH. The present investigation represents an alternative approach for optimizing physicochemical and PK properties of Biopharmaceutical Classification System class-III drugs without changing its molecular structure and intrinsic bioactivities.


  • Open Access

    Changes in plasma biochemical parameters and hormones during transition period in Beetal goats carrying single and twin fetus

    by Jyotsana Madan, Sonia Sindhu, Manoj Kumar Rose

    Aim: The study was undertaken to find out the changes in biochemical and hormonal profile during transition period in single- and twin-bearing Beetal goats. Materials and Methods: Beetal goats are reared in North India for milk and meat purposes, popularly called poor man's cow, serving as a source of livelihood. The present study was conducted on Beetal goats, maintained at a goat farm, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, for characterization of plasma biochemical and hormonal changes during transitional phase in pregnant goats carrying single and twin fetus. The animals selected were expected to have parturition at the same time, to avoid environmental variation effects, and divided into two groups: Group 1 (carrying single fetus, n=14) and Group 2 (twin fetus, n=6). Blood samples were collected from goats prepartum (–30 days and –15 days), 0 day, and postpartum +15 days and +30 days, and plasma was separated for the analysis of biochemical metabolites and hormones by commercially available kits. Results: Analysis of data revealed a significant decrease in triglyceride and cholesterol concentration during postpartum days. A significant increase in alanine aminotransferase (ALT) concentration was observed at the day of parturition. Furthermore, there was a significant (p≤0.05) decrease in ALT and aspartate aminotransferase concentration in goats at the 15th day and 30th day after parturition in both groups. A significant (p≤0.05) lower concentration of total protein and globulins was observed during late pregnancy and on the day of parturition, with a subsequent elevation during postpartum period (15 days and 30 days). Progesterone concentration was highest at –30 days prepartum and decreased sharply at parturition and thereafter postpartum, both in single- and twin-bearing goats. Progesterone level was lower in twin-bearing goats as compared to single-bearing goats at 0 day and postpartum days. No significant changes were observed in sodium, potassium, and chloride concentration during transitional period in goats. Conclusion: Transition period blood metabolite profile changes due to physiological need of mother and fetus were more prominent in metabolites regulating energy requirements and in goats bearing twin fetus.


  • Open Access

    Formulation and In Vitro Evaluation of Casein Nanoparticles as Carrier for Celecoxib

    by Jyotsana R. Madan, Izharahemad N. Ansari, Kamal Dua, Rajendra Awasthi

    Purpose : The objective of this work was to formulate casein (CAS) nanocarriers for the dissolution enhancement of poorly water soluble drug celecoxib (CLXB). Methods: The CLXB loaded CAS nanocarriers viz., nanoparticles, reassembled CAS micelles and nanocapsules were prepared using sodium caseinate (SOD-CAS) as a carrier to enhance the solubility of CLXB. The prepared formulations were characterized for particle size, polydispersity index, zeta potential, percentage entrapment efficiency, and surface morphology for the selection of best formulation. Fourier transform infrared spectroscopy, differential scanning calorimetry and X-ray powder diffraction study was used to for the confirmation of encapsulation of CLXB. Further, in vitro drug dissolution, ex-vivo permeation studies on chicken ileum and stability studies were carried out. Results: The CLXB loaded casein nanoparticles (CNP) (batch A2) showed a particle size diameter 216.1 nm, polydispersity index 0.422 with percentage entrapment efficiency of 90.71% and zeta potential of -24.6 mV. Scanning electron microscopy of suspension confirmed globular shape of CNP. The in vitro release data of optimized batch followed non Fickian diffusion mechanism. The ex vivo permeation studies on chicken ileum of CLXB loaded CNP showed permeation through mucous membrane as compared to pure CLXB. The apparent permeability of best selected freeze dried CLXB loaded CNP (batch A2) was higher and gradually increased from 0.90 mg/cm2 after 10 min to a maximum of 1.95 mg/cm2 over the subsequent 90 min. A higher permeation was recorded at each time point than that of the pure CLXB. Conclusion: The study explored the potential of CAS as a carrier for solubility enhancement of poorly water soluble drugs.


  • Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast

    by Jyotsana R. Madan, Shweta Khobaragade, Kamal Dua, Rajendra Awasthi

    This work was aimed to formulate topical Apremilast loaded nanostructured lipid‐carriers (NLCs) for the management of psoriasis. NLCs were prepared by a cold homogenization technique using Compritol 888ATO, oleic acid, Tween 80 and Span 20, and Transcutol P as a solid lipid, liquid lipid, surfactant mixture and penetration enhancer, respectively. Carbopol 940 was used to convert NLC dispersion into NLC based hydrogel to improve its viscosity for topical administration. The optimized formulation was characterized for size, polydispersity index, zeta potential, percentage entrapment efficiency (%EE), and surface morphology. Further, viscosity, spreadability, stability, in‐ vitro drug diffusion, ex‐vivo skin permeation and skin deposition studies were carried out. Apremilast loaded NLCs showed a narrow polydispersity index (PDI‐ 0.339) with particle size of 758 nm, %EE of 85.5% and zeta potential of −33.3 mV. Scanning electron microscopy confirmed spherical shape of NLCs. In vitro drug diffusion and ex vivo skin permeation results showed low drug diffusion and sustained drug release and 60.1% skin deposition. The present study confirms the potential of the nanostructured lipid form of poorly water‐soluble drugs for topical application and increased drug deposition in the skin.


  • Formulation, Optimization, and Evaluation of Ketoconazole Loaded Nanostructured Lipid Carrier Gel for Topical Delivery

    by Hemant A. Ranpise, Kishore N. Gujar, Sachin C. Pawar, Rajendra Awasthi, Kamal Dua, Dyandevi Mathure, Jyotsana R. Madan

    Objective: Ketoconazole is used in the treatment of superficial and systemic fungal infections. It acts by blocking the synthesis of ergosterol, an essential component of the fungal cell membrane. The purpose of this work was to formulate ketoconazole loaded nanostructured lipid carriers formulation for skin targeting to minimize the adverse side effects and to prolong release. Methods: The ketoconazole loaded nanostructured lipid carriers were optimized using 32 factorial design to evaluate the effects of process and formulation variables. The nanostructured lipid carriers were prepared by melt-dispersion ultra-sonication method. The formulations were finally incorporated into polymeric gels of Carbopol 940 for convenient application. The gels were evaluated comparatively with commercially available formulations of ketoconazole with respect to ex vivo skin permeation and deposition study on human cadaver skin. Results: Nanostructured lipid carriers showed average particle size, zeta potential, and percentage entrapment in the range of 125.8 ± 1.8 to 295.0 ± 3.8 nm, -13.2 ± 1.1 to -30.9 ± 2.2 mV, and 69.47 ± 2.8 to 95.49 ± 4.5, respectively. Thermal studies revealed no drug-excipient incompatibility and amorphization of ketoconazole. Ex vivo study of the gel exhibited prolonged drug release up to 12 h. In vitro drug deposition study showed that the gel formulation can avoid the systemic uptake, better accumulative uptake of the drug, and nonirritant to the skin compared to marketed formulation. Optimized formulation exhibited better antifungal activity when compared to ketoconazole loaded gel and marketed cream (Keto ® cream). Histolopathology results indicated no toxic effect on the skin. Conclusion: These results indicate that developed nanostructured lipid-carriers gel formulation represents a promising carrier for topical delivery of ketoconazole, having controlled drug release, and potential of skin targeting.


  • Open Access

    Formulation, optimization and in vitro evaluation of nanostructured lipid carriers for topical delivery of apremilast

    by Jyotsana R Madan, Shweta Khobaragade, Kamal Dua, Rajendra Awasthi

    This work was aimed to formulate topical Apremilast loaded nanostructured lipid-carriers (NLCs) for the management of psoriasis. Psoriasis is a widespread skin condition considered to be a Th1 autoimmune skin disease and characterized by excessive growth and abnormal differentiation of keratinocytes. Objective of the study was to investigate the applicability of lipid matrix of NLC composed of solid lipid and liquid lipid (oil), creating imperfections in the crystal lattice, in improving drug loading as well as physical stability. NLCs were prepared by a cold homogenization technique using Compritol® 888ATO, oleic acid, Tween 80 and Span 20, and Transcutol P as a solid lipid, liquid lipid, surfactant mixture and penetration enhancer, respectively. Carbopol 940 was used to convert NLC dispersion into NLC based hydrogel to improve its viscosity for topical administration. The optimized formulation was characterized for size, polydispersity index, zeta potential, percentage entrapment efficiency (%EE), and surface morphology. Further, viscosity, spreadability, stability, in- vitro drug diffusion, ex-vivo skin permeation and skin deposition studies were carried out. Apremilast loaded NLCs showed narrow polydispersity index (PDI- 0.339) with particle size of 758 nm, %EE of 85.5% and zeta potential of -33.3 mV. Scanning electron microscopy confirmed spherical shape of NLCs. In vitro drug diffusion and ex vivo skin permeation results showed low drug diffusion and sustained drug release and 60.1% skin deposition. The present study confirms the potential of the nanostructured lipid form of poorly water-soluble drugs for topical application and increased drug deposition in the skin.


  • Emerging Complexity and the Need for Advanced Drug Delivery in Targeting Candida Species

    by Ridhima Wadhwa, Parijat Pandey, Gaurav Gupta, Taru Aggarwal, Nitesh Kumar, Meenu Mehta, Saurabh Satija, Monica Gulati, Jyotsna R. Madan, Harish Dureja, et al.

    Background: Candida species are the important etiologic agents for candidiasis, the most prevalent cause of opportunistic fungal infections. Candida invasion results in mucosal to systemic infections through immune dysfunction and helps in further invasion and proliferation at several sites in the host. The host defence system utilizes a wide array of the cells, proteins and chemical signals that are distributed in blood and tissues which further constitute the innate and adaptive immune system. The lack of antifungal agents and their limited therapeutic effects have led to high mortality and morbidity related to such infections.Methods: The necessary information collated on this review has been gathered from various literature published from 1995 to 2019.Results: This article sheds light on novel drug delivery approaches to target the immunological axis for several Candida species (C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. rugose, C. hemulonii, etc.).Conclusion: It is clear that the novel drug delivery approaches include vaccines, adoptive transfer of primed immune cells, recombinant cytokines, therapeutic antibodies, and nanoparticles, which have immunomodulatory effects. Such advancements in targeting various underpinning mechanisms using the concept of novel drug delivery will provide a new dimension to the fungal infection clinic particularly due to Candida species with improved patient compliance and lesser side effects. This advancement in knowledge can also be extended to target various other similar microbial species and infections.